Literature DB >> 6935907

Restricted dissemination of clinically defined attacks in an MS incidence material.

O Andersen.   

Abstract

Mesh：

Year:  1980        PMID： 6935907

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN： 0065-1427


× No keyword cloud information.
  7 in total

1.  Clinical characteristics of multiple sclerosis in Västerbotten County in northern Sweden.

Authors:  P Sundström; A Svenningsson; L Nyström; L Forsgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Authors:  J Lycke; B Svennerholm; E Hjelmquist; L Frisén; G Badr; M Andersson; A Vahlne; O Andersen
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

3.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

4.  Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study.

Authors:  O Andersen; P E Lygner; T Bergström; M Andersson; A Vahlne
Journal:  J Neurol       Date:  1993-07       Impact factor: 4.849

5.  Prediction of outcome in multiple sclerosis based on multivariate models.

Authors:  B Runmarker; C Andersson; A Odén; O Andersen
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

Review 6.  Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.

Authors:  T Bergström
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970

7.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.